Astellas and Seattle Genetics’ antibody-drug conjugate is at it again. On Saturday, the duo revealed data showing that enfortumab vedotin, along with Merck’s Keytruda, shrank 71% of tumors and wiped out 13% of them in patients with advanced urothelial cancer who had not undergone any other cancer treatment.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,